Thomson David, an insider at MannKind Corp (MNKD), purchased 901,719 shares of the company on December 1, 2025, at a price of $4.55 per share, totaling approximately $4.10 million. Following this transaction, David holds a total of 901,719 shares in the biopharmaceutical firm.
MannKind Corp is focused on developing and commercializing innovative therapeutic products for serious unmet medical needs, particularly in the areas of cardiometabolic and orphan lung diseases. The company, headquartered in Danbury, Connecticut, has a market capitalization of $1.6 billion and reported a P/E ratio of 54.78 and an EPS of 0.09 as of November 25, 2025. Its notable products include Afrezza, an ultra-rapid-acting inhaled insulin, and Tyvaso DPI, used for treating pulmonary arterial hypertension.
This insider buying activity may be interpreted as a show of confidence in the company's future prospects, given that executives often have access to non-public information. However, investors are advised to consider insider transactions as part of a broader analysis, looking for patterns across multiple insiders and time periods rather than relying solely on individual trades.
MannKind's upcoming earnings report is scheduled for May 6, 2026, with an estimated EPS of $0.01 and projected revenue of $101.5 million.